COR vs GIPL vs NEOG Stock Comparison

Cencora, Global Innovative Platforms and Neogen Prices as of Oct 29, 2026 Peers: Industry group
1 more company in this comparison (GRDN) Create a free account to keep reading and compare up to 10 companies.
COR Cencora, Inc.
$330.64 +7.5% 1M -0.8% 1Y
Market cap
$63.87B
P/E
24.3x
Revenue (TTM)
$332.77B
Div. yield
0.01%
Drug Distribution Healthcare
7 wins
NEOG Neogen Corp
$12.26 -3.7% 1M +96.8% 1Y
Market cap
$2.56B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

10 decided of 12

Cencora leads on 7 of the 12 questions below (Cencora 7, Neogen 2, Global Innovative Platforms 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCORGIPLNEOGLeader
Larger companyMarket capitalisation $63.87B $24.88M $2.56B COR
Cheaper on earningsLower P/E, profitable companies only 24.3x -36.0x -45.6x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.4x — 38.3x COR
Faster revenue growthRevenue growth, trailing twelve months +5.1% — -0.3% COR
More profitableNet margin, trailing twelve months 0.8% -361.7% -6.3% COR
Better return on capitalReturn on invested capital 14.4% — -0.2% COR
Less leveragedLower net debt / EBITDA 2.2x 0.4x 5.4x GIPL
Higher dividend yieldTrailing dividend yield 0.01% — 0.00% –
Better 1-year returnPrice return, last 12 months -0.8% -37.5% +96.8% NEOG
Better 5-year returnAnnualised price return, 5 years +22.1%/yr -36.9%/yr -22.0%/yr COR
Less volatileAnnualised volatility, 1 year 32.8% 270.9% 55.7% COR
Higher overall scoreMean of the five percentile scores vs peers 54/100 55/100 57/100 NEOG

Percentile Scorecard

CORGIPLNEOG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCORGIPLNEOG
Valuation 63 #10 of 25 62 #237 of 624 73 #62 of 227
Growth 74 #7 of 24 27 #438 of 601 49 #111 of 218
Profitability 61 #10 of 24 40 #327 of 541 63 #76 of 202
Financial Health 24 #20 of 26 98 #12 of 647 47 #125 of 233
Shareholder Returns 47 #9 of 16 50 #181 of 359 55 #59 of 130
Overall 54 55 57
  • COR ranked among 27 companies in Healthcare Payers and Distributors
  • GIPL ranked among 671 companies in Pharmaceuticals and Biotechnology
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCORGIPLNEOGSPY
1 month +7.5%0.0%-3.7% +0.7%
3 months +5.9%0.0%+6.3% +3.7%
6 months +7.3%-3.8%+30.4% +7.1%
Year to date -2.1%+354.5%+75.4% +12.8%
1 year -0.8%-37.5%+96.8% +11.9%
3 years +78.3%-52.4%-18.6% +85.2%
3 years, per year +21.3%-21.9%-6.6% +22.8%
5 years +171.0%-90.0%-71.0% +67.6%
5 years, per year +22.1%-36.9%-22.0% +10.9%
10 years +378.2%-79.2%-37.3% +262.0%
10 years, per year +16.9%-14.5%-4.6% +13.7%

Risk

MeasureCORGIPLNEOGSPY
Volatility, 1Y 32.8%270.9%55.7% 12.7%
Downside volatility, 1Y 39.7%—46.7% 12.6%
Beta vs S&P 500, 1Y -0.162.261.44 1.00
Return / volatility, 1Y -0.02-0.141.74 0.94
Max drawdown, 5Y -32.6%-98.0%-90.6% -25.4%
From 52-week high -11.8%-49.5%-12.3% -1.2%
52-week high $374.75$0.99$13.98 $779.14
52-week low $252.74$0.11$5.41 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCORGIPLNEOG
P/E now vs peer median 24.3xmedian 24.3x -36.0xmedian 17.8x -47.7xmedian 28.7x
P/S now vs peer median 0.2xmedian 0.3x 132.9xmedian 9.1x 3.0xmedian 3.0x
EV/EBITDA now vs peer median 17.5xmedian 12.9x -39.5xmedian 15.0x 29.6xmedian 17.8x
P/FCF now vs peer median 15.5xmedian 16.4x -32.5xmedian 21.7x 53.7xmedian 26.4x
P/B now vs peer median 19.5xmedian 2.5x 46.8xmedian 2.2x 1.3xmedian 2.4x
PEG now vs peer median 1.36median 1.36 -0.57median 0.35 1.70median 0.99

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCORGIPLNEOG
Revenue $332.77B $187.20K $883.99M
Gross profit $13.22B – $418.98M
Operating income $3.04B -$677.04K -$7.38M
Net income $2.65B -$677.04K -$56.10M
Free cash flow $4.06B -$766.04K $49.80M
R&D – $377.99K $19.76M
EPS (diluted) $13.53 $-0.02 $-0.26
Cash & equivalents $2.82B $244.24K $172.00M
Total debt $11.72B $8.62K $774.20M
Shares (diluted) 193.94M 44.54M 218.10M
Enterprise value $52.77B $24.27M $1.89B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCORGIPLNEOG
P/E 24.3x -36.0x -47.7x
P/FCF 15.5x -32.5x 53.7x
P/Operating cash flow 13.1x -35.0x 31.4x
P/S 0.2x 132.9x 3.0x
P/B 19.5x 46.8x 1.3x
P/Tangible book -23.4x 47.1x 3.4x
EV/EBITDA 17.5x -39.5x 29.6x
EV/EBIT 23.7x -36.4x -444.4x
EV/Revenue 0.2x 131.6x 3.7x
EV/FCF 17.7x -32.2x 65.8x
EV/Operating cash flow 14.9x -34.7x 38.4x
PEG (3Y EPS CAGR) 1.36 -0.57 1.70

Growth

14 metrics
MetricCORGIPLNEOG
Revenue growth (1Y) 5.1% – -0.3%
Revenue CAGR (3Y) 9.4% – -1.3%
Gross profit growth (1Y) 20.0% – 1.8%
Gross profit CAGR (3Y) 15.0% – -3.1%
Operating income growth (1Y) 11.1% -20.9% 99.3%
Operating income CAGR (3Y) 9.5% -51.6% -29.0%
Net income growth (1Y) 38.9% -20.9% 94.6%
Net income CAGR (3Y) 16.2% -51.6% -28.3%
EPS growth (1Y) 39.3% -9.8% 94.6%
EPS CAGR (3Y) 17.9% 63.5% -28.0%
Operating cash flow growth (1Y) 176.7% 15.8% -1.9%
Operating cash flow CAGR (3Y) 14.1% -96.8% 2.9%
Free cash flow growth (1Y) 255.7% 9.2% 1,631%
Free cash flow CAGR (3Y) 13.3% -101.8% 126.1%

Profitability

14 metrics
MetricCORGIPLNEOG
Gross margin 4.0% – 47.4%
EBITDA margin 1.2% -333.4% 12.5%
Operating margin 0.9% -361.7% -0.8%
Pretax margin 1.1% -361.7% -7.7%
Net margin 0.8% -361.7% -6.3%
FCF margin 1.2% -409.2% 5.6%
Operating cash flow margin 1.4% -379.8% 9.6%
Return on equity 77.4% -120.8% -2.7%
Return on assets 3.2% -119.7% -1.7%
Return on invested capital 14.4% – -0.2%
Return on capital employed 12.9% -121.4% -0.2%
Asset turnover 4.0x 0.3x 0.3x
Cash conversion (OCF / net income) 1.8x 1.1x -1.5x
Stock comp / revenue 0.0% – 1.3%

Financial Health

11 metrics
MetricCORGIPLNEOG
Debt / assets 14.0% 1.0% 23.4%
Debt / equity 3.6x 0.0x 0.4x
Net debt / EBITDA 2.2x 0.4x 5.4x
Debt / FCF 2.9x 0.0x 15.5x
Liabilities / assets 96.1% 1.4% 36.8%
Equity / assets 3.9% 98.6% 63.2%
Interest coverage – – –
Current ratio 0.9x 34.7x 3.9x
Quick ratio 0.5x 33.2x 2.1x
Cash ratio 0.0x 31.3x 1.2x
Altman Z-score 4.66 1,908 1.50

Shareholder Returns

7 metrics
MetricCORGIPLNEOG
Dividend yield 0.7% – –
Net buyback yield 1.6% -3.2% -0.1%
Shareholder yield 2.3% -3.2% -0.1%
Payout ratio (earnings) 17.7% – –
Payout ratio (FCF) 11.5% – –
Dividend growth (1Y) 8.7% – –
Dividend CAGR (3Y) 5.7% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCORGIPLNEOG
Forward P/E 19.4xFY2026 – 38.3xFY2026
EPS, next fiscal year $17.08FY2026 – $0.32FY2026
EPS growth, next FY +6.7%FY2026 – 0.0%FY2026
EPS growth, the year after +11.8% – +31.3%
Revenue, next fiscal year $328.56BFY2026 – $847.28MFY2026
Revenue growth, next FY +2.2%FY2026 – -2.7%FY2026
Revenue growth, the year after -0.3% – -1.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCORGIPLNEOG
Held by institutions 94.7% – 100.0%
Institutions holding 1,344 – 315
Change in shares held, QoQ +15.7% – +1.6%
Institutions buying 542 – 151
Institutions selling 611 – 106
Buyers to sellers 0.89 – 1.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CORGIPLNEOG
COR 1.00 0.00 -0.05
GIPL 0.00 1.00 0.01
NEOG -0.05 0.01 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, COR, GIPL and NEOG?

Cencora (COR) is the largest by market capitalisation: Cencora (COR) $63.87B, Global Innovative Platforms (GIPL) $24.88M, Neogen (NEOG) $2.56B.

Which company is growing faster?

Cencora (COR) grew revenue fastest over the trailing twelve months: Cencora (COR) +5.1%, Neogen (NEOG) -0.3%.

Which company is more profitable?

Cencora (COR) has the highest net margin (Cencora (COR) 0.8%, Global Innovative Platforms (GIPL) -361.7%, Neogen (NEOG) -6.3%). On return on invested capital, Cencora (COR) leads (Cencora (COR) 14.4%, Neogen (NEOG) -0.2%).

Which stock has performed better?

Over the past year Neogen (NEOG) returned the most: Cencora (COR) -0.8%, Global Innovative Platforms (GIPL) -37.5%, Neogen (NEOG) +96.8%. Over five years, Cencora (COR) compounded fastest (Cencora (COR) +22.1%/yr, Global Innovative Platforms (GIPL) -36.9%/yr, Neogen (NEOG) -22.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Cencora (COR) 0.01%, Neogen (NEOG) 0.00%. Global Innovative Platforms (GIPL) and Neogen (NEOG) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Cencora (COR) has been the steadiest (Cencora (COR) 32.8%, Global Innovative Platforms (GIPL) 270.9%, Neogen (NEOG) 55.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, COR, GIPL and NEOG?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cencora (COR) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.